Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial

Tetsu Hayashida, Hiromitsu Jinno, Katsuaki Mori, Hiroki Sato, Akira Matsui, Takashi Sakurai, Hiroaki Hattori, Shin Takayama, Masahiro Wada, Maiko Takahashi, Hirohito Seki, Tomoko Seki, Aiko Nagayama, Akiko Matsumoto, Yuko Kitagawa

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial'. Together they form a unique fingerprint.

Medicine & Life Sciences